Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × quizartinib × Sarcoma × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡